{"id":880773,"date":"2025-09-02T08:51:34","date_gmt":"2025-09-02T12:51:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/"},"modified":"2025-09-02T08:51:34","modified_gmt":"2025-09-02T12:51:34","slug":"ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/","title":{"rendered":"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025"},"content":{"rendered":"
\n

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th<\/sup> Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled \u201cThe FDA Gauntlet: Strategies for a Successful Run at Approval\u201d during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany.<\/p>\n

\u201cYear after year, the H.C. Wainwright Global Investment Conference provides a great opportunity for us to meet with key investors in the biotech and healthcare space,\u201d said Dr. Musunuri. \u201cI look forward to broadening our reach into the European investment community during Biotech on Tap.\u201d<\/p>\n

In addition to Dr. Musunuri\u2019s sessions, members of Ocugen\u2019s executive team will conduct one-on-one meetings to showcase the Company\u2019s business and clinical development strategy across its unique modifier gene therapy platform.<\/p>\n

Details for Dr. Musunuri\u2019s sessions are as follows:<\/p>\n

H.C. Wainwright 27th<\/sup> Annual Global Investment Conference
Date: Monday, September 8, 2025
Fireside Chat\u00a0Time: 5 p.m. ET
Location: Adams, 4th<\/sup> Floor, Lotte New York Palace Hotel, NYC<\/p>\n

Biotech on Tap
Date: Thursday, September 25, 2025
Panel Time: 3:30 p.m. CET
Location: EY Auditorium, Munich, Germany<\/p>\n

A live video webcast of the fireside chat will be available on the\u00a0events<\/a>\u00a0page of the Ocugen\u00a0investor site<\/a>. The webcast replay will be archived for 90 days following the event.<\/p>\n

\n About Ocugen, Inc.<\/strong>
\n
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen\u2019s modifier gene therapies address the entire disease\u2014complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy\u2014late stage dry age-related macular degeneration. Discover more at\u00a0www.ocugen.com<\/a>\u00a0and follow us on\u00a0X<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n Cautionary Note on Forward-Looking Statements<\/strong>
\n
\n This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled \u201cRisk Factors\u201d in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/em>\n <\/p>\n

\n Contact:<\/strong>
\n
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled \u201cThe FDA Gauntlet: Strategies for a Successful Run at Approval\u201d during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany. \u201cYear after year, the H.C. Wainwright Global Investment Conference provides a great opportunity for us to meet with key investors in the biotech and healthcare space,\u201d said Dr. Musunuri. \u201cI look … <\/p>\n

Continue reading “Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-880773","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOcugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled \u201cThe FDA Gauntlet: Strategies for a Successful Run at Approval\u201d during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany. \u201cYear after year, the H.C. Wainwright Global Investment Conference provides a great opportunity for us to meet with key investors in the biotech and healthcare space,\u201d said Dr. Musunuri. \u201cI look … Continue reading "Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-02T12:51:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025\",\"datePublished\":\"2025-09-02T12:51:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/\"},\"wordCount\":576,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/\",\"name\":\"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=\",\"datePublished\":\"2025-09-02T12:51:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/","og_locale":"en_US","og_type":"article","og_title":"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025 - Market Newsdesk","og_description":"MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled \u201cThe FDA Gauntlet: Strategies for a Successful Run at Approval\u201d during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany. \u201cYear after year, the H.C. Wainwright Global Investment Conference provides a great opportunity for us to meet with key investors in the biotech and healthcare space,\u201d said Dr. Musunuri. \u201cI look … Continue reading \"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-02T12:51:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025","datePublished":"2025-09-02T12:51:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/"},"wordCount":576,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/","name":"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=","datePublished":"2025-09-02T12:51:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMTM3NSM3MTIyNjc4IzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen to Participate in H.C. Wainwright 27th Annual\u00a0Global Investment Conference & Biotech on Tap 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=880773"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880773\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=880773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=880773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=880773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}